Bronib®

Ibrutinib

Product Information

  • Proprietary Name: Bronib®
  • Generic Name: Ibrutinib
  • Dosage Form: Hard Gelatin Capsule
  • Strengths: 140 mg
  • Indications: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Waldenstrom’s Macroglobulinemia, Marginal Zone Lymphoma, Chronic Graft versus Host Disease

Oncology

Bronib®

Ibrutinib is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), waldenstrom’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.

Ready to get started?

Curious about a specific position? Sign up for it.
© NanoAlvand. All rights reserved. Powered by ِDGN.